913251-58-8

Basic information

• Product Name: (S)-2-tert-butoxycarbonylamino-5-oxo-hexanoic acid ethyl ester
• Synonyms: (S)-2-tert-butoxycarbonylamino-5-oxo-hexanoic acid ethyl ester;ethyl (S)-2-((tert-butoxycarbonyl)amino)-5-oxohexanoate
• CAS NO: 913251-58-8
• Molecular Formula: C₁₃H₂₃NO₅
• Molecular Weight: 273.32542
• Mol File: 913251-58-8.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-2-tert-butoxycarbonylamino-5-oxo-hexanoic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-tert-butoxycarbonylamino-5-oxo-hexanoic acid ethyl ester(913251-58-8)
• EPA Substance Registry System: (S)-2-tert-butoxycarbonylamino-5-oxo-hexanoic acid ethyl ester(913251-58-8)

Safety Data

• Hazardous Substances Data: 913251-58-8(Hazardous Substances Data)

Usage

General Description

(S)-2-tert-butoxycarbonylamino-5-oxo-hexanoic acid ethyl ester is a chemical compound with the molecular formula C13H23NO5. It is an ethyl ester derivative of (S)-2-tert-butoxycarbonylamino-5-oxo-hexanoic acid, which is a known inhibitor of serine proteinases. (S)-2-tert-butoxycarbonylamino-5-oxo-hexanoic acid ethyl ester is commonly used in biochemical research as a substrate for proteolytic enzymes and for studying enzymatic reactions. Additionally, it has potential applications in drug development and as a building block for the synthesis of other compounds. However, it is important to handle this chemical with care as it can be hazardous if not used properly.

Upstream product

• 75-16-1 methylmagnesium bromide 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 

Downstream Products

• 1378391-45-7 tert-butyl (2S,4S)-2-[5-(2-{(2S,5S)-1-[N-(methoxycarbonyl)-L-valyl]-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine-1-carboxylate 
• 1844064-96-5 (2S,4S)-2-[5-(2-{(2S,4S)-1-{N-(methoxycarbonyl)-L-valyl}-5-methylpyrrolidin-2-yl}-1,11-dihydroisochromene[4',3':6,7]naphtho[1,2-d]imidazol-9-yl)-1H-imidazol-2-yl]-4-(methoxymethyl)pyrrolidine 
• 1377049-84-7 methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1377050-12-8 methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-methylpyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1378392-97-2 methyl [(2S)-3-methyl-1-{(2S,5S)-2-methyl-5-[9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,11-dihydroisochromeno[4′,3′:6,7]naphtho[1,2-d]imidazol-2-yl]pyrrolidin-1-yl}-1-oxobutan-2-yl]carbamate 
• 1378390-35-2 (2S,5S)-2-(2-(9-bromo-8-oxo-8,9,10,11-tetrahydro-5H-dibenzo[c,g]chromen-3-yl)-2-oxoethyl) 1-tert-butyl 5-methylpyrrolidine-1,2-dicarboxylate 
• 1334123-94-2 (2S,5S)-tert-butyl 2-methyl-5-(tosyloxymethyl)pyrrolidine-1-carboxylate 
• 1334123-87-3 C₂₄H₃₅FN₂O₃ 
• 676560-84-2 (2S,5S)-5-methylpyrrolidine-2-carboxylic acid ethyl ester 
• 676560-83-1 (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 334769-80-1 (2S,5S)-5-methyl-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 
• 1433280-50-2 [(S)-2-methyl-1-((2S,5S)-2-methyl-5-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-propyl]carbamic acid methyl ester 
• 1378390-49-8 ((S)-1-{(2S,5S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-5-methyl-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 
• 1250939-15-1 (2S,5S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-5-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Compound used for inhibiting hepatitis C virus, and pharmaceutical applications thereof

The invention relates to a compound which is represented by formula I, is used for inhibiting hepatitis C virus, and possesses excellent bioavailability, and a nontoxic pharmaceutically acceptable salt thereof. The compound possesses extremely high inhibition effect on HCV of all genotypes. In the formula I, R is used for representing hydrogen atom, glycyl, L-alanyl, L-leucyl, L-valyl, or L-isoleucyl.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.

PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS

The present disclosure provides processes for the preparation of a compound of formula: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates.